Turner
syndrome is a
chromosomal condition, which occurs when one of the two X chromosomes normally
found in women is missing or incomplete. The disease alters the growth and
development in females. The symptoms can vary among women who have Turner
syndrome. Women with this condition tend to be shorter than average and are
usually unable to conceive a child because of an absence of ovarian function.
Access
Detailed Report Summary: https://www.pharmaproff.com/report/turner-syndrome-therapeutics-pipeline-analysis
Some other
features of this condition are extra skin on the neck (webbed neck), heart
defects and kidney problems, puffiness or swelling (lymphedema) of the hands
and feet, and skeletal abnormalities. This condition occurs in about one in
2,500 female births worldwide, but is much more common among pregnancies that
do not survive to term (miscarriages and stillbirths).
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1149
The drug
candidates of Turner syndrome disease pipeline include, but are not limited to
are Estradiol and Somatropin pegylated. Some of the companies having drugs in
the Turner syndrome disease pipeline are Novo Nordisk A/S, GeneScience
Pharmaceuticals Co. Ltd., and Polus Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment